Engflag

Imagliv

Quick links to important sections

Imagliv

Selected form

Imagliv_EN

Method of action: Antitumour

Treatment option: Hypereosinophilic Syndrome, Dermatofibrosarcoma Protuberans, Leukemia, Acute Lymphoblastic Leukemia, Chemotherapy, Surgery, Chronic Myeloid Leukemia, Chronic Eosinophilic Leukemia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imagliv

Quick Facts

Property Description
Active ingredient Imatinib mesylate
Form Tablet or Oral Solution
Pharmacological class Tyrosine Kinase Inhibitor (TKI)
Common use (General) To control the progression of certain malignancies and blood disorders
Origin Synthetic, Small Molecule Inhibitor

What is Imagliv and What is it Made Of?

Imagliv refers to the active substance Imatinib (INN), a synthetic, prescription-only medication that represents a foundational therapy in the modern approach known as targeted therapy. The active compound is supplied as Imatinib mesylate, which is a single-ingredient product designed for oral use, primarily available as a solid tablet. A key differentiating factor for Imatinib is its flexibility in administration: the tablets can be dissolved in water or apple juice for patients who have difficulty swallowing, confirming the medication's adaptability for diverse patient needs.

What Type of Medicine is Imagliv?

Imagliv is classified as an Antineoplastic Agent and, more specifically, as a Tyrosine Kinase Inhibitor (TKI), a designation that is clinically recognized by health authorities. This classification means the drug is specifically designed to interfere with the growth and survival signals of cancer cells. Imatinib is considered a highly selective inhibitor, demonstrating significant efficacy and tolerability compared to older, non-selective treatments, which marked a major turning point in clinical practice.

What is the General Purpose of Imagliv?

The general purpose of Imagliv is to control the progression of diseases driven by the abnormal activity of targeted enzymes. It functions by achieving selective inhibition of specific proteins, such as the Bcr-Abl tyrosine kinase associated with the Philadelphia chromosome (Ph+) abnormality. By blocking these abnormal signals, Imagliv prevents the continuous, uncontrolled cellular proliferation (rapid cell growth) that characterizes these conditions, thereby promoting apoptosis (programmed cell death) instead.

What side effects are possible with Imagliv?

Classification of Officially Listed Adverse Reactions

The safety profile for Imagliv (Imatinib mesylate) is formally classified by regulatory authorities, grouping potential effects by frequency and the body system affected. This classification demonstrates a high occurrence of gastrointestinal disturbances and fluid retention/edema within the very common category.

Frequency Classification Representative Adverse Reactions (System-Organ Class)
Very Common (≥ 1/10) Gastrointestinal (Nausea, vomiting, diarrhea, abdominal pain), Musculoskeletal (Muscle spasms, joint pain), Dermatological (Rash), General (Fluid retention/edema, fatigue, headache)
Common (≥ 1/100 to < 1/10) General (Weakness, fever), Metabolic (Weight increase, loss of appetite), Dermatological (Hair loss, pruritus)

Documented Serious Adverse Reactions and Safety Constraints

Official government documents highlight several serious adverse reactions and necessary safety constraints, even if observed at Uncommon or Rare frequencies.

  • Serious Adverse Reactions: These include severe forms of fluid retention (e.g., pulmonary edema), severe hepatotoxicity (liver injury or failure), congestive heart failure, and severe gastrointestinal events like perforation or hemorrhage.
  • Safety Constraints: Routine monitoring of blood counts and liver function tests is a mandated requirement of the official label. Monitoring of fluid status and weight is also necessary due to the risk of fluid retention.

Population and Exposure-Related Notes

  • Timing: Fluid retention is often documented as more frequently observed at the beginning of treatment or during dose escalation.
  • Special Populations: Patients with severe hepatic impairment require safety precautions and monitoring. In pediatric patients, the label notes that specific monitoring is required for potential effects on growth and musculoskeletal development.

Overdose and Emergency Response

Imagliv Overdose and When to Seek Help

Overdose Scope Official Regulatory Information
Documented overdose presentations Manifestations reported following exposures up to 10 grams include severe nausea, vomiting, and diarrhea, along with rash, edema, headache, and muscle cramps/spasms [Source: FDA/EMA]. Overdose in pediatric patients has been associated with transient gastrointestinal symptoms.
Physiological systems affected High-dose exposure affects the Gastrointestinal, Hematologic, Hepatic, and Renal systems. Severe outcomes may include acute kidney failure and elevated liver transaminases, in addition to myelosuppression (low white blood cell and platelet counts) [Source: EMA SmPC].
Dose-related factors Exposures of up to 10,000 mg (10 grams) in a single dose have been reported, demonstrating the potential for serious toxicity at these levels [Source: EMA SmPC]. The risk of severe fluid retention is noted to increase with higher doses, particularly in elderly patients [Source: FDA Label].
When immediate medical help is required Patients must seek immediate medical attention or contact a poison control center in the event of suspected overdose [Source: MedlinePlus]. Immediate help is required due to the risk of severe or life-threatening systemic damage.

Overdose Classifications (High-Level)

Classification Official Regulatory Information
Severity classification Regulatory documents classify potential outcomes as severe or life-threatening, based on the risks of acute kidney and hepatic failure [Source: EMA SmPC].
Antidote status No specific antidote is known for Imatinib [Source: FDA Label].
Mandatory monitoring Close patient monitoring is required, involving frequent assessments of blood counts and liver function tests [Source: EMA SmPC].

Official Overdose Statements:

  • Management of overdose is defined as symptomatic and supportive treatment.
  • Gastric lavage may be considered based on clinical necessity following recent ingestion of a large dose.

Connection to the Overall Overdose Profile

Regulatory documents emphasize that the overdose profile is defined by severe hematologic, hepatic, and renal toxicities, which necessitate immediate emergency action and specialized supportive care. The absence of a known antidote confirms that management focuses on mitigating documented organ-specific manifestations and continuous clinical observation, as required by health authorities.

Therapeutic Uses of Imagliv

What Imagliv Treats: Main Uses and Benefits

Imagliv is a specific therapeutic agent used for malignancies characterized by disruptive symptom patterns. This medicine is primarily indicated for the management of Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), Gastrointestinal Stromal Tumors (GIST), and rare conditions such as Aggressive Systemic Mastocytosis (ASM).

This support is relevant for managing the systemic symptom burden that creates noticeable physiological strain. It is often applied during phases when symptoms become more noticeable, particularly in advanced or relapsed settings.

“This therapy contributes to long-term disease management, helping patients cope more steadily with symptom fluctuations and supporting general well-being.”

For solid tumors, the focus is on assisting with the stabilization of tumor manifestations, which may help ease tumor-related physical symptoms and supports the patient during difficult episodes. In rare blood disorders, the therapy may contribute to reducing the risk of organ-specific functional stress.

Quick Fact: Support for Systemic Symptom Burden Category Therapeutic Focus
Symptom Axis Symptoms related to systemic imbalance and functional strain.
Common Scenario Adjuvant care or treatment for advanced, unresectable disease.
Benefit Supports stability and eases the overall symptom load.

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Imagliv (Imatinib mesylate) is permitted for use in adults and pediatric patients aged 1 year and older for its labeled indications. The sole absolute contraindication, as documented by regulatory bodies, is known hypersensitivity to imatinib or any of its excipients.

Eligibility Restrictions

Pregnancy and Lactation: Use during pregnancy is not recommended due to the potential for fetal harm; females of reproductive potential must use effective contraception. Breastfeeding is not recommended during treatment and for a specified time after the final dose.

Age and Organ Function: Safety and efficacy are not established in children younger than 1 year. Patients with severe hepatic impairment are eligible but require a dose reduction. Use in severe renal impairment (CrCl <20 mL/ min) is generally not recommended due to insufficient data. Older adults are eligible but require close monitoring for fluid retention.

Special Conditions: Patients with pre-existing cardiac disease or those who have had a thyroidectomy and are on levothyroxine replacement require special monitoring as a condition of use.

What should I know about interactions with other medicines?

Imagliv (Imatinib) has a high potential for clinically significant interactions, primarily due to its role in the body’s metabolic processes. The drug is mainly metabolized by the enzyme CYP3A4 and is an inhibitor of several other cytochrome P450 enzymes, including CYP3A4 and CYP2D6. This metabolic profile makes Imagliv both a substrate (victim) and an inhibitor (perpetrator) of interactions.

Potential Drug and Product Interactions

  • CYP3A4 Inducers: Medicinal products that increase the activity of CYP3A4 (e.g., rifampicin, phenytoin, carbamazepine) can significantly decrease Imagliv's concentration in the bloodstream, which may reduce its effectiveness. The co-administration with strong inducers is generally avoided or requires an increase in the Imagliv dosage under strict monitoring.
  • CYP3A4 Inhibitors: Drugs that block the activity of CYP3A4 (e.g., ketoconazole, clarithromycin) can increase Imagliv's concentration, raising the risk of toxicity. Grapefruit juice should also be avoided as it is a CYP3A4 inhibitor.
  • Anticoagulants: Imagliv can increase the effects of warfarin (a vitamin K antagonist), increasing the risk of bleeding. For patients requiring blood thinning therapy, regulatory documents advise using alternative agents, such as low-molecular weight heparin or standard heparin.
  • Other Substrates: Imagliv can increase the concentration of co-administered drugs that are metabolized by CYP3A4 or CYP2D6 (e.g., simvastatin, metoprolol), potentially increasing their side effects. Caution is required when combining these medicines.
  • Levothyroxine: Patients who have undergone thyroidectomy and are taking levothyroxine replacement therapy must have their Thyroid-Stimulating Hormone (TSH) levels closely monitored, as Imagliv has been reported to induce hypothyroidism in this population.

Mechanism of Action

Imagliv is a selective small molecule inhibitor that exerts its action by interfering precisely with specific enzymatic drivers of cell proliferation. Its mechanism centers on highly selective inhibition of key proteins responsible for the survival of cells dependent on these tyrosine kinases.

Primary Mechanism: Targeting Oncogenic Kinases

Imagliv specifically targets the BCR-ABL fusion protein and related enzymes. It functions as a competitive inhibitor by binding to the ATP-binding site of these tyrosine kinases. By occupying this critical molecular site, the drug prevents the necessary process of tyrosine phosphorylation, which mediates cellular growth and survival signaling. The resulting physiological effect is the direct cessation of hyperactive signaling, which shifts the cells toward apoptosis (programmed cell death) rather than continuous proliferation.

Broader System Modulation and Constraints

The drug's mechanism also modulates other receptor tyrosine kinases, including c-KIT and PDGFR, which are important in regulating cell growth and function in other tissues. This action results in the modulation of signal transduction across multiple related systems. However, the mechanism is limited by molecular changes, such as point mutations in the target enzyme (e.g., T315I), or by increased activity of drug efflux transporters. These limitations structurally compromise the drug's ability to bind, thereby reducing its inhibitory effect and allowing the signaling pathway activity to continue.

Dosage and Administration Information

How Imagliv Is Used: Official Administration Guidelines

Imagliv (Imatinib mesylate) is administered orally according to structured guidelines defined by health authorities to ensure consistent and appropriate use. Its usage is primarily characterized by a standardized daily dose regimen and specific requirements for intake context and administration flexibility.

Instruction Parameter Official Usage
Administration Route The medicine is prescribed exclusively for oral intake.
Standard Dosing Starting doses are typically 400 mg or 600 mg once daily, with the precise amount dependent on the patient's specific condition as noted in the prescribing label. Doses may be increased, where clinically indicated, up to a maximum of 800 mg per day.
Frequency Pattern Administration is generally once daily (QD). However, the maximum daily dose of 800 mg requires the medicine to be taken in divided doses (twice daily).
Intake Context Imagliv must be taken with a meal and a large glass of water. This instruction is essential for ensuring optimal absorption and minimizing gastrointestinal irritation.
Preparation Flexibility For individuals who have difficulty swallowing, tablets can be dispersed in a controlled volume of non-carbonated water or apple juice before intake. The tablets should otherwise be swallowed whole.
Dose Adjustments Specific modifications are instructed for certain patient populations; notably, a starting dose reduction of approximately 25% is required for patients with hepatic impairment. Pediatric dosing is calculated based on Body Surface Area (BSA).
Missed Dose Rule If a scheduled dose is missed, official guidelines advise the patient to take the next dose at the regularly scheduled time and not to take an extra dose to compensate for the oversight.

Imagliv is typically used as part of a long-term, continuous treatment plan for most indications. For certain conditions, such as adjuvant treatment for Gastrointestinal Stromal Tumors (GIST), a defined duration of 36 months is specified in the clinical use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Imagliv

Imagliv (Imatinib) has been evaluated in numerous clinical studies, including large, multi-center Randomized Controlled Trials (RCTs), long-term observational follow-up studies, and trials focusing on specific populations. The research examined outcomes related to changes in disease status, including the measurement of specific biomarkers. The evidence was evaluated in research published in peer-reviewed journals and reviewed by governmental health authorities.

Evidence for Chronic Myeloid Leukemia (CML) Studies

Clinical evidence for CML primarily comes from large, global RCTs. These pivotal trials were studied for adult patients with newly diagnosed, Philadelphia chromosome-positive (Ph+) CML in the chronic phase, comparing Imatinib to another treatment, which was the standard protocol at the time. Researchers monitored outcomes such as Overall Survival, the time until the disease progressed to a more advanced stage, and changes in specific molecular and genetic biomarkers that track the disease's presence.

Studies reported that the cohorts receiving Imatinib showed patterns related to achieving key molecular and cytogenetic response milestones; comparisons were made against the established treatment at the time. Progression to advanced phases was observed in the research, and data show patterns related to different rates in the Imatinib group versus the comparator group. This research contributes to the broader evidence landscape by offering extended observation periods for this patient group.

Evidence for Gastrointestinal Stromal Tumors (GIST) Studies

For unresectable or metastatic GIST, research examined outcomes such as Overall Survival, Progression-Free Survival, and rates of tumor stabilization or shrinkage. Findings describe patterns observed in the studies where tumor stabilization or shrinkage (Objective Response) was observed in the studied cohorts. For adjuvant GIST, Randomized Controlled Trials were evaluated in high-risk patients following tumor removal. Trials reported that the cohort receiving the medicine was associated with differences in Recurrence-Free Survival compared to the observation group.

Evidence Gaps and Areas of Scientific Uncertainty

While the evidence is extensive, areas where certainty remains low include the optimal duration of therapy and the comparative evidence against newer treatments for advanced CML. Data are still emerging regarding which patients can safely stop the drug without risk of relapse.

Frequently Asked Questions (FAQ)

Common questions about Imagliv (FAQ)

Q: What is the primary condition Imagliv is approved to treat?

Imagliv is officially indicated for the maintenance treatment of moderate to severe asthma in adults and adolescents who are already receiving inhaled corticosteroids and a long-acting beta-agonist. According to the official product information, it is used to help improve asthma control and reduce the frequency of severe asthma attacks. Regulatory information specifies that Imagliv is not intended for the relief of acute or sudden asthma flare-ups.

Q: Does Imagliv cure asthma or just manage symptoms?

Regulatory documents state that Imagliv is a maintenance treatment for asthma, meaning it is designed to help control the condition over time. It works to reduce the frequency and severity of asthma attacks, but it is not a cure for asthma. Regulatory documents emphasize the importance of continuing other prescribed asthma treatments unless otherwise directed by a healthcare professional.

Q: Is Imagliv used for all types of asthma?

Imagliv is specifically approved for the treatment of moderate to severe asthma in adults and adolescents. Official information indicates that its use is restricted to individuals who have not achieved adequate control with standard treatments, which include a combination of inhaled corticosteroids and a long-acting beta-agonist (LABA).

Q: What happens if I forget to take a dose of Imagliv?

The official product information generally outlines that a missed dose may be taken when remembered, unless it is close to the time of the next scheduled dose. If the next dose is due soon, the missed dose should be skipped, and the patient should resume their regular dosing schedule. The labeling specifies that patients should avoid taking a double dose to compensate for a missed one.

Q: Is it safe to suddenly stop taking Imagliv when my asthma feels better?

Official product information cautions against abruptly stopping Imagliv, even when asthma symptoms appear to improve. Discontinuing the medication abruptly can lead to a worsening of asthma control and an increased risk of severe flare-ups. Any decision to modify or stop the treatment plan should be made in consultation with a prescribing healthcare provider.

Q: Can I use Imagliv as a rescue inhaler for an acute asthma attack?

No, Imagliv is not a rescue medication. Studies and official information indicate that it is intended only for long-term, maintenance control of asthma. It does not work quickly enough to stop an acute, sudden asthma attack. For sudden breathing problems, official guidance directs the use of a fast-acting rescue inhaler as prescribed by a healthcare professional.

Q: Does taking Imagliv require regular blood tests or monitoring?

Official regulatory documents do not specify routine or frequent blood tests related to the use of Imagliv at its standard maintenance dose. However, a healthcare professional may recommend periodic follow-up appointments to monitor overall asthma control and assess the ongoing effectiveness of the therapy. This monitoring may include checking lung function.

How should Imagliv be stored and disposed of?

Storage and Disposal Requirements for Imagliv (Imatinib Mesylate)

Imagliv tablets must be stored under specific conditions to maintain stability and ensure safety, as directed by regulatory labeling.

Storage Conditions

Mandatory Storage: Store at Room Temperature, generally not exceeding 30 C. The container must be kept tightly closed and stored in a dry place to protect the contents from moisture. To prevent accidental ingestion, the medication must always be stored out of the reach of children and secured.

Handling and Disposal

Special Handling: If a tablet is broken or crushed, contact with the medication must be avoided. Any area that contacts the contents must be washed thoroughly. Immediate administration is required if the tablet is dispersed in liquid. Disposal of unused or expired Imagliv must follow local regulations; the product must not be flushed down the toilet or released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Imagliv found in:

A-Z Index: